Aurora Cannabis Inc. ($ACB) Stock Forecast: Down 5.4% Today

What is Aurora Cannabis Inc.?

Aurora Cannabis Inc. (ACB) is focusing on the global medical cannabis market, emphasizing regulated international markets like Germany, Australia, and Poland.

Why is Aurora Cannabis Inc. going down?

ACB stock is down 5.4% on Mar 5, 2026 19:36

• The recent decline in ACB's stock price may be linked to the company's shift away from lower-margin Canadian consumer markets in favor of medical cannabis operations.
• Investors are anxious about potential short-term financial effects as Aurora Cannabis makes this transition, prompting them to sell off the stock.
• Despite positive analyst outlooks and a "Buy" rating suggesting a 66% upside, market sentiment is cautious as the company undergoes this strategic change, potentially leading to stock price fluctuations.
• Targeting lucrative international medical markets such as Germany and Australia, though promising for future growth, is generating uncertainty among investors in the immediate term, contributing to the stock's recent bearish trend.

ACB Price Chart

ACB Technical Analysis

ACB News

Aurora Cannabis announces pivot to ‘solely’ medical distribution

Aurora Cannabis Inc. is making a strategic pivot to focus exclusively on medical cannabis operations, exiting lower-margin Canadian consumer markets. This shift aims to capitalize on high-margin, regulated international medical markets such as Germany, Australia, and Poland. Despite a 96% stock plummet since 2021, analysts are optimistic about the company's future with a "Buy" rating and a potential 66% upside.

https://mugglehead.com/aurora-cannabis-announces-pivot-to-solely-medical-distribution/?utm_source=rss&utm_medium=rss&utm_campaign=aurora-cannabis-announces-pivot-to-solely-medical-distribution

Canadian LP Aurora Cannabis is now ‘solely’ a medical company

Aurora Cannabis is transitioning to focus "solely" on the global medical cannabis market, stepping away from adult-use recreational cannabis. This strategic shift is driven by higher margins and less price compression in regulated medical markets like Germany, Australia, and Poland, aligning with the company's emphasis on profitability. The medical segment already accounts for 81% of Aurora's total revenue and 95% of its adjusted gross profit, reflecting a strategy years in the making.

https://mjbizdaily.com/news/canadian-lp-aurora-cannabis-is-now-solely-a-medical-company/614790/

Canaccord Initiates Aurora Cannabis Inc. (ACB) With C$10 Price Target

Canaccord Genuity initiated coverage of Aurora Cannabis Inc. (ACB) with a Buy rating and a C$10 price target, recognizing it as a leading medical cannabis operator in Canada and key international markets. The firm highlights Aurora's strategic shift to a medical-first model, which has led to higher-margin international expansion and is expected to drive profitability. Aurora reported strong Q3 fiscal 2026 results, with medical revenue constituting 81% of total net revenue and 95% of adjusted gross profit, and issued positive guidance for fiscal 2026.

https://finance.yahoo.com/news/canaccord-initiates-aurora-cannabis-inc-202413768.html

Aurora Cannabis Pivots to Medical-Only, Eyes Germany & Australia Growth at TD Cowen Conference

Aurora Cannabis is shifting its focus exclusively to medical cannabis, prioritizing high-margin, regulated international markets like Germany and Australia. The company reported CAD 94 million in revenue, with global medical revenue up 7% year-over-year, and boasts industry-leading profitability with margins in the mid-to-high 60s%. This strategy involves scaling back its Canadian consumer business, divesting a plant propagation unit, and expanding internal GMP manufacturing to ensure reliable, pharmaceutical-grade supply.

https://finance.yahoo.com/news/aurora-cannabis-pivots-medical-only-223241919.html

Cannabis Jobs Update – March 2026

This article provides an update on the Canadian cannabis job market in March 2026, highlighting continued growth and new opportunities across various provinces. It lists specific job openings from numerous companies in retail, cultivation, production, and other sectors within the cannabis industry. The article aims to connect job seekers with available positions throughout Canada.

https://stratcann.com/news/cannabis-jobs-update-march-2026/

Trending Today

ZCash ($ZEC) Crypto Forecast: Up 20.2% Today

Ethereum ($ETH) Crypto Forecast: Up 11.6% Today

Heating Oil ($HEATOIL) Commodity Forecast: Down 5.3% Today

Shiba Inu ($SHIB) Crypto Forecast: Up 5.8% Today

Brent Crude Oil ($BRENT) Commodity Forecast: Down 5.2% Today

Intel Corporation ($INTC) Stock Forecast: Down 5.3% Today

Dogecoin ($DOGE) Crypto Forecast: Up 7.4% Today

Beyond Meat Inc. ($BYND) Stock Forecast: Up 5.6% Today

Bumble Inc. ($BMBL) Stock Forecast: Up 5.6% Today

Digital Ocean Holdings ($DOCN) Stock Forecast: Up 5.1% Today

Aurora Cannabis Inc. Price History

13.01.2026 - ACB Stock was up 5.6%

• The positive movement in ACB's stock today is linked to the company's decision to restructure its investment in Bevo Agtech, selecting preferred shares with a 5% annual dividend and additional shareholder protections. This strategic move underscores Aurora's focus on creating a more efficient capital structure and prioritizing its core cannabis operations.
• Furthermore, Aurora's upcoming participation in ringing the Nasdaq closing bell to highlight its shift towards being a medical-first, globally oriented cannabis company could have boosted investor confidence, contributing to the favorable market sentiment.
• The company's expansion of its medical cannabis portfolio in Australia and New Zealand by introducing new products derived from its unique genetics further demonstrates its dedication to global expansion and meeting the changing needs of healthcare professionals and patients. This expansion likely spurred optimism among investors about Aurora's long-term prospects in international markets, fueling the positive movement in its stock.

21.00.2026 - ACB Stock was up 4.1%

• The surge in Aurora Cannabis Inc. (ACB) stock today is linked to the company obtaining Community Plant Variety Rights in the EU for its cannabis varieties, 'Farm Gas' and 'Sourdough'. This move reinforces Aurora's market position and underscores its dedication to innovative and high-quality products.
• Gaining exclusive rights for the commercial production and distribution of these potent cannabis strains across the EU's 27 member states marks a significant milestone that is likely to enhance investor confidence in Aurora's growth potential.
• Furthermore, the potential implications of President Trump's executive order to reclassify cannabis to Schedule 3, potentially easing the tax burden under Section 280E for U.S. cannabis companies, could have also influenced the positive outlook on Aurora Cannabis and the broader cannabis sector.

20.01.2026 - ACB Stock was up 6.3%

• Aurora Cannabis CFO's participation in a healthcare conference and discussion of international leadership and manufacturing trends in medical cannabis likely boosted investor confidence in the company's strategic direction.
• The completion of the Bevo transaction aimed at diversifying Aurora's portfolio and strengthening its competitive position could have positively influenced market sentiment.
• Positive analyst ratings and recommendations, along with being highlighted as one of the top investment choices in the cannabis sector, might have attracted more investors to ACB, contributing to its bullish movement.
• The overall positive outlook for Aurora Cannabis, including strong fiscal performance and debt-free status, could have further supported the bullish trend in the stock price.

05.02.2026 - ACB Stock was down 5.4%

• The recent decline in ACB's stock price may be linked to the company's shift away from lower-margin Canadian consumer markets in favor of medical cannabis operations.
• Investors are anxious about potential short-term financial effects as Aurora Cannabis makes this transition, prompting them to sell off the stock.
• Despite positive analyst outlooks and a "Buy" rating suggesting a 66% upside, market sentiment is cautious as the company undergoes this strategic change, potentially leading to stock price fluctuations.
• Targeting lucrative international medical markets such as Germany and Australia, though promising for future growth, is generating uncertainty among investors in the immediate term, contributing to the stock's recent bearish trend.

05.01.2026 - ACB Stock was down 7.2%

• Aurora Cannabis (ACB) stock faced a strong bearish movement today, dropping by 7.9% to reach a new 52-week low.
• Despite posting positive Q3 earnings, including a 7% increase in net revenue and achieving positive free cash flow, the stock declined by 7.2%. Factors contributing to this decline were anticipated Q4 one-time cash costs, an inventory write-off, and a significant decrease in consumer cannabis revenue.
• The announcement of a U.S.$100 million at-the-market share program by Aurora Cannabis may have influenced the bearish sentiment due to concerns about potential dilution and future capital requirements.
• Analysts have maintained an average "Buy" rating with a consensus price target of C$9.25 for Aurora Cannabis, despite adjusting a few targets downward. This indicates a varied sentiment in the market regarding the company's future performance.

11.01.2026 - ACB Stock was down 5.2%

• ACB posted strong Q3 fiscal 2026 results, exceeding earnings and sales expectations primarily due to its medical cannabis division, but its stock faced a downward trend.
• The launch of a US$100 million ATM equity scheme with TD Securities hints at potential share dilution ahead, likely influencing investors' pessimism.
• The company's shift towards global markets and decision to withdraw from certain Canadian consumer cannabis sectors may have sparked doubts about its growth strategy, impacting stock performance.
• Varying analyst ratings and the focus on boosting profitability through operational efficiencies have possibly created investor uncertainty, contributing to the downtrend in ACB shares.

29.00.2026 - ACB Stock was down 5.0%

• The recent "buy" rating from Canaccord Genuity Group may have initially boosted investor sentiment, but the subsequent stock price decline suggests potential concerns regarding Aurora Cannabis's profitability and revenue performance.
• While surpassing earnings per share (EPS) expectations, missing revenue estimates could have eroded investor confidence, contributing to the sell-off.
• Varying analyst ratings and active trading by institutional investors indicate uncertainty and potential profit-taking, intensifying the downward pressure on the stock.
• Aurora Cannabis's overall decline may stem from reevaluations of its financial well-being and growth prospects in the competitive cannabis sector, overshadowing any positive market performance on Thursday.

04.01.2026 - ACB Stock was down 8.7%

• The launch of four new websites by Aurora Cannabis Inc. showcasing its science-backed cannabis leadership in European markets did not have the desired positive impact on the stock price.
• Despite the company's continued investment and commitment to the region, investors may have been expecting more concrete developments or financial results rather than just digital initiatives.
• The lack of immediate market reaction to the website launch suggests that investors are looking for more substantial growth drivers or positive financial indicators to drive the stock price higher.
• The bearish movement in ACB's stock today could be attributed to profit-taking by traders following a period of relative stability or a broader negative sentiment in the cannabis sector.

04.01.2026 - ACB Stock was down 7.4%

• The bearish movement in ACB stock today could be attributed to profit-taking by investors after a recent positive earnings report and strategic announcements.
• The launch of a U.S.$100 million at-the-market share program may have raised concerns among investors about potential dilution of existing shares, leading to a sell-off.
• Despite the positive revenue growth and focus on the medical cannabis market, the market sentiment might have been impacted by the company's near 52-week low stock price and the perceived oversold position highlighted by analysts.
• The overall market reaction to the strategic shifts and global growth initiatives of Aurora Cannabis seems to be mixed, with investors possibly taking a cautious approach amid uncertainties surrounding the company's future profitability and capital raising activities.

06.01.2026 - ACB Stock was up 5.0%

• Aurora Cannabis established a US$100 million ATM equity program with TD Securities to improve its financial flexibility, which has been positively viewed by investors.
• The company reported modest revenue growth in Q3 FY26. However, its strong performance in the global medical cannabis market and strategic focus on key international markets such as Germany, Australia, and Poland have garnered investor support, leading to an optimistic movement in the stock.
• Aurora's decision to exit select Canadian consumer cannabis markets and streamline operations to boost profitability has instilled confidence in investors regarding the company's future growth prospects.
• Despite the dip in Aurora Cannabis shares following the Q3 results showing modest revenue growth, the market's positive reaction to the company's strategic shift towards higher-margin medical markets and operational efficiency has resulted in a rebound in the stock price.

03.02.2026 - ACB Stock was down 5.3%

• Investors may question the growth potential of Aurora Cannabis in the recreational cannabis market as the company shifts exclusively to medical cannabis and targets regulated international markets.
• The strategic shift, including reducing focus on the Canadian consumer business and expanding GMP manufacturing, could be seen as a defensive response to industry challenges, leading to a negative sentiment among traders.
• Despite analysts predicting a potential 66.60% upside for ACB stock, doubts remain about the company's ability to leverage future market trends given concerns about its track record, net losses, and limited presence in the U.S. market.
• Market insights and trading signals suggesting a weak long-term rating for ACB:CA align with the observed bearish movement, reflecting a lack of confidence in the company's future growth prospects.

29.11.2025 - ACB Stock was down 5.3%

• ACB stock experienced a bearish movement, sliding by 1.72% and underperforming the market.
• The underperformance could be attributed to overall market sentiment towards the cannabis sector or company-specific factors.
• The mention of Unity Software's strong financial results in a recent communication may have inadvertently highlighted ACB's own underwhelming performance, leading to a further decline in its stock price.
• Investors may have reacted negatively to the quarterly loss reported by Unity Software, potentially signaling concerns about profitability in the tech sector, which could have spilled over to impact ACB's stock negatively.